Granted Patent
B2
US 12,502,357 · App. 18/967,829 · Granted Dec 23, 2025
Formulations of enzalutamide
Inventors:
Douglas Alan Lorenz (Bend, OR); Sanjay Konagurthu (Bend, OR); Randy J. Wald (Bend, OR); Jason A. Everett (Bend, OR); Sheila Matz (North Conway, NH); Yuuki Takaishi (Tokyo, JP); Toshiro Sakai (Tokyo, JP); Ryousuke Irie (Tokyo, JP); Shinsuke Oba (Tokyo, JP); Hiroyasu Toyota (Tokyo, JP); Koji Nishimura (Tokyo, JP); Atsushi Kanbayashi (Tokyo, JP)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
Claims (1)
1 . A method of treating prostate cancer comprising administering to a patient in need thereof a tablet comprising a solid dispersion comprising amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate.
Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 16, 2025
From: MATZ, SHEILA
To: MEDIVATION PROSTATE THERAPEUTICS, INC.
Reel/Frame 071727/0071 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 16, 2025
From: TAKAISHI, YUUKI; SAKAI, TOSHIRO; IRIE, RYOUSUKE; OBA, SHINSUKE; TOYOTA, HIROYASU; NISHIMURA, KOJI; KANBAYASHI, ATSUSHI
To: ASTELLAS PHARMA INC.
Reel/Frame 071727/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 16, 2025
From: LORENZ, DOUGLAS ALAN; KONAGURTHU, SANJAY; WALD, RANDY J.; EVERETT, JASON A.
To: BEND RESEARCH
Reel/Frame 071727/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 16, 2025
From: MEDIVATION LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 071728/0265 →
CHANGE OF ADDRESS
Recorded Jul 16, 2025
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 071982/0068 →
CHANGE OF ADDRESS
Recorded Jul 16, 2025
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 071982/0161 →
CHANGE OF ADDRESS
Recorded Jul 16, 2025
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 071982/0163 →
CHANGE OF NAME
Recorded Jul 16, 2025
From: MEDIVATION PROSTATE THERAPEUTICS, INC.
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 071982/0166 →
CONFIRMATORY ASSIGNMENT
Recorded Jul 16, 2025
From: LORENZ, DOUGLAS ALAN; KONAGURTHU, SANJAY; WALD, RANDY J.; EVERETT, JASON A.
To: BEND RESEARCH, INC.
Reel/Frame 071982/0354 →
CONFIRMATORY ASSIGNMENT
Recorded Jul 16, 2025
From: BEND RESEARCH, INC.
To: MEDIVATION LLC
Reel/Frame 071982/0458 →
Continuity (13)
Continuation
18670353
· May 21, 2024
Continuation
18387149
· Nov 6, 2023
Continuation
17662278
· May 6, 2022
Continuation
17487546
· Sep 28, 2021
Continuation
17178580
· Feb 18, 2021
Continuation
16924656
· Jul 9, 2020
Continuation
16693655
· Nov 25, 2019
Provisional Application
61699351
· Sep 11, 2012
References Cited (400)
US 6899899B2
· Takagi et al.
· 2005
[cited by applicant]
US 7189415B2
· Takagi et al.
· 2007
[cited by applicant]
US 7709517B2
· Sawyers et al.
· 2010
[cited by applicant]
US 7780988B2
· Beyerinck et al.
· 2010
[cited by applicant]
US 8183274B2
· Sawyers et al.
· 2012
[cited by applicant]
US 8445507B2
· Jung et al.
· 2013
[cited by applicant]
US 8865894B2
· Caravatti
· 2014
[cited by examiner]
US 20010053778A1
· Hoover et al.
· 2001
[cited by applicant]
US 20020009494A1
· Curatolo
· 2002
[cited by examiner]
US 20020031547A1
· Takagi et al.
· 2002
[cited by applicant]
US 20040074350A1
· Hanada
· 2004
[cited by applicant]
US 20050038111A1
· Bateman et al.
· 2005
[cited by applicant]
US 20060079706A1
· Parthasaradhi et al.
· 2006
[cited by applicant]
US 20070004753A1
· Sawyers et al.
· 2007
[cited by applicant]
US 20080181960A1
· Doney
· 2008
[cited by applicant]
US 20100297194A1
· Catron et al.
· 2010
[cited by applicant]
US 20100310659A1
· Desai et al.
· 2010
[cited by applicant]
US 20110020455A1
· Yoshida et al.
· 2011
[cited by applicant]
US 20140100256A1
· Lorenz et al.
· 2014
[cited by applicant]
US 20140179749A1
· Lorenz et al.
· 2014
[cited by applicant]
US 20140378517A1
· Lorenz et al.
· 2014
[cited by applicant]
US 20150216813A1
· Everett et al.
· 2015
[cited by applicant]
US 20150239848A1
· Peddy et al.
· 2015
[cited by applicant]
US 20170027910A1
· Lorenz et al.
· 2017
[cited by applicant]
US 20170224624A1
· Lorenz et al.
· 2017
[cited by applicant]
US 20170267645A1
· Peddy et al.
· 2017
[cited by applicant]
US 20220347102A1
· Fradera Gelabert et al.
· 2022
[cited by applicant]
EP 0901786A2
· 1999
[cited by applicant]
EP 0901786B1
· 1999
[cited by applicant]
EP 1368001B1
· 2005
[cited by applicant]
EP 1741424A1
· 2007
[cited by applicant]
EP 1741424A2
· 2007
[cited by applicant]
EP 1893196B1
· 2008
[cited by applicant]
EP 1893196B2
· 2015
[cited by applicant]
EP 1741424B1
· 2018
[cited by applicant]
EP 3725778A1
· 2020
[cited by applicant]
EP 3725778B1
· 2021
[cited by applicant]
EP 3971167A1
· 2022
[cited by applicant]
WO WO200109143A1
· 2001
[cited by applicant]
WO WO2002067893A2
· 2002
[cited by applicant]
WO WO2003032950A1
· 2003
[cited by applicant]
WO WO2003033508A1
· 2003
[cited by applicant]
WO WO2003043606A1
· 2003
[cited by applicant]
WO 03063821
· 2003
[cited by examiner]
WO WO2003063821A2
· 2003
[cited by applicant]
WO WO2003089499A1
· 2003
[cited by applicant]
WO WO2004074350A2
· 2004
[cited by applicant]
WO WO2006123223A1
· 2006
[cited by applicant]
WO WO2006124118A1
· 2006
[cited by applicant]
WO WO2007016435A2
· 2007
[cited by applicant]
WO WO2008110534A1
· 2008
[cited by applicant]
WO WO2010114928A2
· 2010
[cited by applicant]
WO WO2011106570A1
· 2011
[cited by applicant]
WO WO2011112558A2
· 2011
[cited by applicant]
WO WO2013184681A1
· 2013
[cited by applicant]
WO WO2014042945A1
· 2014
[cited by applicant]
WO WO2014043208A1
· 2014
[cited by applicant]
WO WO2014167428A2
· 2014
[cited by applicant]
WO WO2018199282A1
· 2018
[cited by applicant]
Anonymous, Highlights of Prescribing Xtandi, FDA. (Year: 2012).
[cited by examiner]
Jannsens et al, Physical Chemistry of Solid Dispersions, Journal of Pharmacy and Pharmacology, vol. 61, No. 12, pp. 1571-1586. (Year: 2009).
[cited by examiner]
Accord Healthcare Limited, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Al-Obaidi & Buckton, “Evaluation of Griseofulvin Binary and Ternary Solid Dispersions with HPMCAS,” AAPS PharmSciTech 10, 1172-77, 2009.
[cited by applicant]
Alfred E. Tiefenbacher (GmbH & Co. KG), Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Alhalaweh et al., “Physical stability of drugs after storage above and below the glass transition temperature: Relationship to glass-forming ability,” Int. J. Pharm. 495, 312-17, 2015.
[cited by applicant]
Ali et al., “The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs,” Int. J. Pharmaceutics 453, 225-32, available online Jul. 3, 2012.
[cited by applicant]
Ambike et al., “Stability study of amophrous valdecoxib,” Int. J. Pharmaceutics 282, 151-62, 2004.
[cited by applicant]
Amended Claims filed Aug. 21, 2023 in Invalidation Action Against TW Patent I673051, including English translation, 4 pages.
[cited by applicant]
Andrews et al., “Physicochemical Characterization of Hot Melt Extruded Bicalutamide-Polyvinylpyrrolidone Solid Dispersions,” J. Pharmaceut. Sci. 99, 1322-35, 2010.
[cited by applicant]
Anonymous, “A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects,” ClinicalTrials.gov identifier NCT01911741, J…
[cited by applicant]
Anonymous, “Enzalutamide and difficulty swallowing the capsules,” available at databankws.lareb.nl/Downloads/Signals_2016_Enzalutamidedysphagia.pdf, 2 pages, 2016.
[cited by applicant]
Anonymous, Excerpt from the National Drug Code Directory for XTANDI dated Mar. 31, 2022.
[cited by applicant]
Anonymous, Press Release, “U.S. FDA Approves XTANDI® (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel,” Astellas.com, Sep. 1, 2012.
[cited by applicant]
Aulton, ed.,
[cited by applicant]
Baghel et al., “Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class…
[cited by applicant]
Bend Research, “Spray Drying of Amorphous Dispersions,” Pharmaceutical Technology Europe 24(9), 3 pages, Sep. 2, 2012.
[cited by applicant]
Beringer, et al., Eds.; “Remington: The Science and Practice of Pharmacy; 21st Ed.”; 2005; Lippencott, Williams & Wilkins; pp. 229-230, 675-676, 730.
[cited by applicant]
Bevernage et al., “Evaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issues,” Int. J. Pharmaceutics 453, 25-35, available online Nov. 27, 2012.
[cited by applicant]
Bevernage et al., “Excipient-Mediated Supersaturation Stabilization in Human Intestinal Fluids,” Molecular Pharmaceutics 8, 564-70, Jan. 26, 2011.
[cited by applicant]
Bhatnagar et al., “Solid Dispersion in Pharmaceutical Drug Development: From Basics to Clinical Applications,” Current Drug Delivery 10, 2013, 17 pages.
[cited by applicant]
Broadbent & Bennette, “Fundamentals of Spray-Dried Dispersion Technology,” 2015.
[cited by applicant]
Brough & Williams, “Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery,” Int. J. Pharmaceutics 453, 157-66, available online Jun. 7, 2013.
[cited by applicant]
Buelle, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research 12, 945-54, 1995.
[cited by applicant]
Calahan et al.; “Isothermal Microcalorimetry to Investigate the Phase Separation for Amorphous Solid Dispersions of AMG 517 with HPMC-AS”; Apr. 2013; Mol. Pharmaceutics 2013, 10, 1949-1957.
[cited by applicant]
Calahan, Characterization of Amorphous Solid Dispersions of AMG 517 in HMPC-AS and crystallization using Isothermal Microcalorimetry, Apr. 4, 2011, pp. 1-128.
[cited by applicant]
Cantarini et al., “Pharmacokinetics of Two Novel Bicalutamide Formulations in Healthy Male Volunteers,” Pharmacology 77, 171-78, 2006.
[cited by applicant]
Censi & Di Martino, “Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs,” Molecules 20, 18759-76, 2015.
[cited by applicant]
Center for Drug Evaluation & Research, Product Quality Review for Xtandi® Tablet NDA 213674, 2020.
[cited by applicant]
Center for Drug Evaluation and Research, Index for Approval Package and Approval Letter for Xtandi® capsules dated Aug. 31, 2012, not publicly available before Sep. 12, 2012, 10 pages.
[cited by applicant]
Center for Drug Evaluation and Research, Multi-Discipline Review for Xtandi® Tablets, Jan. 25, 2021.
[cited by applicant]
Center of Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review, submitted May 22, 2012, not publicly available before Aug. 31, 2012, pp. 1-83.
[cited by applicant]
Chiang et al., “Evaluation of Drug Load and Polymer by Using a 96-Well Plate Vacuum Dry System for Aorphous Solid Dispersion Drug Delivery,” AAPS PharmSciTech 13, 713-22, available online May 5, 2012.
[cited by applicant]
Chiang et al., “In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound,” The AAPS Journal 15, 608-17, available online Mar. 2,…
[cited by applicant]
Chokshi et al., “Improving the Dissolution Rate of Poorly Water Soluble Drug by Solid Dispersion and Solid Solution—Pros and Cons,” Drug Delivery 14, 33-45, 2008.
[cited by applicant]
Clegg et al.; “ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment”; Jan. 2012; Cancer Res; 72(6): 1494-1503 & Supplemental pp. 1-13.
[cited by applicant]
Cordes et al.,, “Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer,” The Oncologist 26(9), 729-e1493, 2021.
[cited by applicant]
Curatolo et al., “Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu,” Pharm Res. 26, 1419-31, 2009.
[cited by applicant]
Davis et al., “Amorphous solid dispersions of BCS class II drugs: A rational approach to solvent and polymer selection,” Chemical Engineering Research and Design 110, 192-99, 2016.
[cited by applicant]
DiNunzio et al., “Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol® Dispersing,” Drug Development and Industrial Pharmacy 36, 1064-78, Nov. 5, 2010.
[cited by applicant]
Domingos et al., “New forms of old drugs: improving without changing,” J. Pharmacy and Pharmacology 67, 830-46, 2015.
[cited by applicant]
Dong & Choi, “Hydroxypropyl Methylcellulose Acetate Succinate: Potential Drug-Excipient Incompatibility,” AAPS PharmSciTech 9, 991-97, 2008.
[cited by applicant]
Dr. Schoen Neymeyr & Partner, Opposition to EP3725778 filed May 17, 2022.
[cited by applicant]
Drug Bank Entry for Enzalutamide, available at https://www.drugbank.ca/drugs/DB08899, 9 pages, created on Jun. 4, 2013.
[cited by applicant]
Drugs.com, “Silicon Dioxide”, available online Oct. 29, 2011.
[cited by applicant]
Drugs@FDA, NDA 213674, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213674.
[cited by applicant]
Edueng et al., “Long-Term Physical (In)Stability of Spray-Dried Amorphous Drugs: Relationship with Glass-Forming Ability and Physicochemical Properties,” Pharmaceutics 11, 20 pages, 2019.
[cited by applicant]
Edueng et al., “The Need for Restructuring the Disordered Science of Amorphous Drug Formulations,” Pharm. Res. 34, 1754-72, 2017.
[cited by applicant]
Elder et al., “Aqueous solubility: Simple predictive methods (in silico, in vitro and bio-relevant approaches),” Int. J. Pharmaceutics 453, 3-11, available online Nov. 2, 2012.
[cited by applicant]
Elder et al., “Use of pharmaceutical salts and cocrystals to address the issue of poor solubility,” Int. J. Pharmaceutics 453, 88-100, available online Nov. 24, 2012.
[cited by applicant]
Elkington + Fife, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Environmental Protection Agency, “The Presidential Green Chemistry Challenge Awards Program: Summary of 2009 Award Entries and Recipients,” 71 pages, 2009.
[cited by applicant]
Environmental Protection Agency, “The Presidential Green Chemistry Challenge Awards Program: Summary of 2009 Award Entries and Recipients,” pp. 1-47, 2009.
[cited by applicant]
Environmental Protection Agency, “The Presidential Green Chemistry Challenge Awards Program: Summary of 2010 Award Entries and Recipients,” 58 pages, 2010.
[cited by applicant]
Environmental Protection Agency, “The Presidential Green Chemistry Challenge Awards Program: Summary of 2010 Award Entries and Recipients,” pp. 1-47, 2010.
[cited by applicant]
EP 20177837.0, “Information about non-relevance of third-party observations dated Mar. 15, 2021,” Examiner's statement dated Apr. 9, 2021.
[cited by applicant]
FDA Draft Guidance for Industry, Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations, Mar. 2014, 83 pages.
[cited by applicant]
FDA Draft Guidance on Enzalutamide, Jun. 2015, 2 pages.
[cited by applicant]
FDA Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations, 2002, 27 pages.
[cited by applicant]
FDA list of 2012 approval notifications dated Feb. 13, 2018, 2 pages.
[cited by applicant]
Ferrari et al., “The Surface Roughness of Lactose Particles Can Be Modulated by Wet-Smoothing Using a High-Shear Mixer,” AAPS PharmSciTech 5, 1-6, 2004.
[cited by applicant]
First Examination Report, 2875/DELNP/2015, Aug. 21, 2018, 6 pages.
[cited by applicant]
Friesen et al., “Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview,” Molecular Pharmaceutics 5, 1003-19, available online Dec. 1, 2008.
[cited by applicant]
Fryer et al., “Physical Properties and Effect in a Battery of Safety Pharmacology Models for Three Structurally Distinct Enteric Polymers Employed as Spray-Dried Dispersions Carriers,” Frontiers in Pharmacology 7, 12 pa…
[cited by applicant]
Gao & Shi, “Characterization of Supersaturatable Formulations for Improved Absorption of Poorly Soluble Drugs,” The AAPS Journal 14, 703-13, 2012.
[cited by applicant]
Gao, “Amorphous Pharmaceutical Solids: Characterization, Stabilization, and Development of Marketale Formulations of Poorly Soluble Drugs with Improved Oral Absorption,” Molecular Pharmaceutics 5, 903-04, 2008.
[cited by applicant]
Ghadi & Dand, “BCS class IV drugs: Highly notorious candidates for formulation development,” J. Controlled Release 248, 71-95, 2017.
[cited by applicant]
Ghosh et al., “Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder,” International Journal of Pharmaceutics 419, 12-19, 2011.
[cited by applicant]
Gibson, “Pharmaceutical Preformulation and Formulation. A Practical Guide from Candidate Drug Selection to Commercial Dosage Form,” Interpharm/CRC, vol. 199, 2nd ed., preface, contents, contributors, and chapters 4 and …
[cited by applicant]
Grohganz et al., “Amorphous drugs and dosage forms,” J. Drug Del. Sci. Tech. 23, 403-08, 2013.
[cited by applicant]
Guedes et al., “Solid Dispersions of Imidazolidinedione by PEG and PVP Polymers with Potential Antischistosomal Activities,” AAPS PharmSciTech 12, 401-10, 2011.
[cited by applicant]
Guo et al., “A comparative study on in vitro and in vivo characteristics of enzalutamide nanocrystals versus amorphous solid dispersions and a better prediction for bioavailability based on ‘spring-parachute’ model,” In…
[cited by applicant]
Guo et al., “Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions,” Trends in Analytical Chem. 49, 137-44, 2013.
[cited by applicant]
Gupta et al., “Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems,” ISRN Pharmaceutics 2013, 16 pages.
[cited by applicant]
Hadida, Case History: Kalydeco (VX-770, Ivacaftor), a CTFR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CTFR Mutation, Annual Reports in Medicinal Chemistry 49, 383-98, 2014.
[cited by applicant]
Hamm Wittkopp, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Harris, “Solid Dispersions. A universal formulation strategy for poorly soluble drugs?” available at www.contractpharma.com/issues/2016-04-01/view_features/solid-dispersions-a-universal-formulation-strategy-for-poorly-s…
[cited by applicant]
Holm et al., “Bile salts and their importance for drug absorption,” Int. J. Pharmaceutics 453, 44-55, available online Apr. 15, 2013.
[cited by applicant]
Hong, “Solid Molecular Dispersions of Itraconazole for Enhanced Dissolution and Controlled Drug Delivery,” Thesis submitted to Graduate Department of Pharmaceutical Sciences, University of Toronto, 2009, 92 pages.
[cited by applicant]
Huang & Dai, “Fundamental aspects of solid dispersion technology for poorly soluble drugs,” Acta Pharmaceutica Sinica B 4, 18-25, 2014.
[cited by applicant]
Hugo, “Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations,” Drug Development and Industrial Pharmacy 39, 402-12, 2012.
[cited by applicant]
Incivek®, US Prescribing Information, May 2011, 23 pages.
[cited by applicant]
Int. J. Pharmaceutics 453, Table of Contents, https://www.sciencedirect.com/journal/international-journal-of-pharmaceutics/vol/453/issue/1, 2013.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2013/059223, dated Dec. 20, 2013, 9 pages.
[cited by applicant]
Invalidation Action filed for Taiwan Patent No. 1673051 reported by Taiwan Intellectual Property Office on May 12, 2023, including English translation.
[cited by applicant]
Invalidation Action filed for Taiwan Patent No. 1673051 reported by Taiwan Intellectual Property Office on May 12, 2023, with English translation of Part 1.
[cited by applicant]
Jannin et al., “Approaches for the development of solid and semi-solid lipid-based formulations,” Advanced Drug Delivery Reviews 60, 734-46, 2008.
[cited by applicant]
Janssens and Van den Mooter, “Review: physical chemistry of solid dispersions,” J. Pharmacy Pharmacology 61, 1571-86, 2009.
[cited by applicant]
Joshi et al., “Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture,” International Journal of Pharmaceutics 269, 251-58, 2004.
[cited by applicant]
Kalepu & Nekkanti, “Insoluble drug delivery strategies: review of recent advances and business prospects,” Acta Pharmaceutica Sinica B 5, 422-53, 2015.
[cited by applicant]
Kalepu et al., “Oral lipid-based drug delivery systems—an overview,” Acta Pharmaceutica Sinica B 3(6):361-72, 2013.
[cited by applicant]
Kalydeco®, US Prescribing Information, Feb. 2017, 17 pages.
[cited by applicant]
Kambayashi & Dressman, “Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach,” Journal of Pharmaceutical S…
[cited by applicant]
Kaushal & Bansal, “Thermodynamic behavior of glassy state of structurally related compounds,” Eur. J. Pharmaceutics Biopharmaceutics 69, 1067-76, 2008.
[cited by applicant]
Kawabata et al., “Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability,” European Journal of Pharmaceutical Sciences 39, 256-62, 2010.
[cited by applicant]
Kawahara et al., “Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate-specific antigen level and improvement in radiograp…
[cited by applicant]
Kennedy et al.; “Enhanced Bioavailability of a Poorly Soluble VR1 Antagonist Using an Amorphous Solid Dispersion Approach: A Case Study”; 2008; Molecular Pharmaceutics; 5(6):981-993.
[cited by applicant]
Kollipara & Ghandi, “Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulations,” Acta Pharmaceutica Sinica B 4, 333-49, 2014.
[cited by applicant]
Konno & Taylor, “Ability of Different Polymers to Inhibit the Crystallization of Amorphous Felodipine in the Presence of Moisture,” Pharmaceutical Research 25, 969-78, 2007.
[cited by applicant]
Konno et al., “Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine,” Eur. J. Pharmaceutics Biopharmaceutics 70, 493-99, 2008.
[cited by applicant]
Kumar & Singh, “A Study on Solubility Enhancement Methods for Poorly Water Soluble Drugs,” Am. J. Pharmacol. Sci. 1, 67-73, 2013.
[cited by applicant]
Kumar et al., “Development and Optimization of Enzalutamide-Loaded Solid Lipid Nanoparticles Using Box-Behnken Design,” Asian Journal of Pharmaceutical and Clinical Research 12, 67-76, 2019.
[cited by applicant]
Kurkov & Loftsson, “Cyclodextrins,” Int. J. Pharmaceutics 453, 167-80, available online Jul. 5, 2012.
[cited by applicant]
Kwong, “Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus,” Nature Biotechnology 29, 993-1003, 2011.
[cited by applicant]
Labrasol Technical Data Sheet, May 26, 2020.
[cited by applicant]
LaFountaine et al., “Challenges and Strategies in Thermal Processing of Amorpous Solid Dispersions: A Review,” AAPS PharmSciTech 17, 43-55. 2016.
[cited by applicant]
Laitinen et al., “Emerging trends in the stabilization of amorphous drugs,” Int. J. Pharmaceutics 453, 65-79, available online Apr. 28, 2012.
[cited by applicant]
Lauer et al., “Atomic Force Microscopy-Based Screening of Drug-Excipient Miscibility and Stability of Solid Dispersions,” Pharm. Res. 28, 572-84, 2011.
[cited by applicant]
Lauer et al., “Rapid Assessment of Homogeneity and Stability of Amorphous Solid Disperions by Atomic Force Microscopy—From Bench to Batch,” Pharm. Res. 30, 2010-22, 2013.
[cited by applicant]
Leuner et al., “Improving drug solubility for oral delivery using solid dispersions,” European Journal of Pharmaceutics and Biopharmaceutics 50, 47-60, 2000.
[cited by applicant]
Lin and Wong, “Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models,” Pharmaceutics 9, 41, 2017, 14 pages.
[cited by applicant]
Lissy et al., “Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet,” Expert Opinion on Pharmacotherapy 11:5, 701-08, 2010.
[cited by applicant]
Lobmann et al., “A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin,” Int. J. Pharmaceutics 453, 80-87, available online 18, 2012.
[cited by applicant]
Loftsson, Preface for the special IJP issue “Poorly soluble drugs,” Int. J. Pharmaceutics 453, 1-2, available online Jun. 3, 2013.
[cited by applicant]
Lorenz et al., EP13766437.1 filed Apr. 1, 2015, 99 pages.
[cited by applicant]
Lorenz et al., EP13766437.1 response including claims filed May 22, 2019, 10 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Application Deemed Withdrawn, Jun. 26, 2020, 2 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Communication from Examining Division, Nov. 14, 2018, 4 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Examination Report—Examiner's Statement of Relevance of Third Party Observations, Oct. 2, 2019, 3 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Examiner's communication, Feb. 16, 2017, 4 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Response filed Aug. 25, 2017, 8 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Response to Written Opinion filed Oct. 28, 2015, 5 pages.
[cited by applicant]
Lorenz et al., EP13766437.1, Statement of Non-Relevance of Third Party Observations dated Mar. 15, 2021.
[cited by applicant]
Lorenz et al., EP20177837.0 as filed Jun. 2, 2020, 102 pages.
[cited by applicant]
Lorenz et al., EP20177837.0 response to oppositions filed Dec. 12, 2022, 79 pages.
[cited by applicant]
Lorenz et al., EP20177837.0 Search Opinion, Sep. 17, 2020, 2 pages.
[cited by applicant]
Lorenz et al., EP20177837.0 Search Report, Sep. 8, 2020, 3 pages.
[cited by applicant]
Lorenz et al., EP20177837.0, Intent to Grant and Examiner's Response to Third Party Observations, Mar. 2, 2021, 8 pages.
[cited by applicant]
Lorenz et al., EP20177837.0, “Information about non-relevance of third-party observations,” Examiner's statement dated Apr. 15, 2021.
[cited by applicant]
Lorenz et al., EP20177837.0, “Information about non-relevance of third-party observations,” Examiner's statement dated Apr. 9, 2021.
[cited by applicant]
Lorenz et al., EP20177837.0, EPO Provisional Opinion, Mar. 29, 2023.
[cited by applicant]
Lorenz et al., EP21190086.5, claims filed Oct. 21, 2021, 2 pages.
[cited by applicant]
Lorenz et al., EP21190086.5, Search Opinion, Feb. 1, 2022, 6 pages.
[cited by applicant]
Lorenz et al., EP22197225.7 Search Report and Opinion, Mar. 3, 2023, 12 pages.
[cited by applicant]
Lorenz et al., EP22197255.7 Claims filed Dec. 15, 2022, 3 pages.
[cited by applicant]
Lorenz et al., EP22197255.7 Search Report and Opinion, Mar. 3, 2023, 12 pages.
[cited by applicant]
Lorenz et al., IL237604, Amended Claims filed Mar. 8, 2015, 3 pages.
[cited by applicant]
Lorenz et al., IL237604, First Office Action, English translation, Oct. 24, 2017, 4 pages.
[cited by applicant]
Lorenz et al., IL237604, Notice of Acceptance and Allowed Claims in English, Apr. 8, 2021, 4 pages.
[cited by applicant]
Lorenz et al., IL237604, Petition to Amend Claims dated Nov. 16, 2022 with English translation, 10 pages.
[cited by applicant]
Lorenz et al., IL237604, Response to First Office Action, May 24, 2018, 89 pages.
[cited by applicant]
Lorenz et al., IL237604, Response to Second Office Action with English translation, May 30, 2019, 9 pages.
[cited by applicant]
Lorenz et al., IL237604, Response to Third Office Action with English translation, Oct. 26, 2020, 7 pages.
[cited by applicant]
Lorenz et al., IL237604, Second Office Action, English translation, Jan. 31, 2019, 2 pages.
[cited by applicant]
Lorenz et al., IL237604, Third Office Action, with English translation, Feb. 27, 2020, 6 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,637 claims filed Sep. 11, 2013, 1 page.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,637 claims filed Dec. 24, 2013, 1 page.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,637 non-final Office Action dated Mar. 10, 2014.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,637 response to notice to file corrected application papers, including substitute specification and drawings with claims filed Dec. 24, 2013, 163 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, claims filed Mar. 3, 2014, 3 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, claims filed Sep. 11, 2013.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, final Office Action dated Mar. 17, 2016.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, Non-Final Office Action mailed Jun. 2, 2015, 14 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, response filed Dec. 2, 2015, 17 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, Restriction Requirement mailed Dec. 1, 2014, 7 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/023,878, preliminary amendment and response to Notice to Corrected Application Papers, including substitute specification with claims filed Mar. 3, 2014, 214 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/481,986 claims filed Sep. 10, 2014, 1 page.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/481,986, Final Office Action mailed Sep. 9, 2015, 12 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/481,986, non-final Office Action dated Feb. 25, 2015, 8 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 14/481,986, response filed Jul. 27, 2015, 13 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, claims filed Feb. 8, 2016, 1 page.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, final office action, 14 pages, mailed Aug. 21, 2017.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, interview summary dated Sep. 19, 2018.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, non-final Office Action dated Apr. 2, 2018.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, non-final Office Action dated Nov. 25, 2016, 12 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, response filed Feb. 21, 2018.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/018,078, response filed May 25, 2017, 14 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/267,352 Preliminary Amendment and response to Restriction Requirement filed Dec. 1, 2017, 7 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/267,352 restriction requirement dated Jun. 12, 2017.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/267,352, application filed Sep. 16, 2016, 101 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/267,352, non-final Office Action mailed Jan. 25, 2018, 21 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/267,352, preliminary amendment filed May 1, 2017, 7 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/268,352 Nonfinal Office Action dated May 28, 2019.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 15/267,352, response filed Dec. 1, 2017, 7 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/044,255 preliminary amendment filed Mar. 27, 2019.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/044,255, filed Jul. 24, 2018, 88 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/044,255, Office Action dated May 28, 2019, 21 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 claims filed Apr. 1, 2019.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 final Office Action dated Nov. 10, 2021.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 final Office Action dated Sep. 21, 2020.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 Koleng Declaration filed Mar. 22, 2021.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 non-final Office Action dated Mar. 29, 2021.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 response filed Mar. 22, 2021.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 response filed Sep. 28, 2021.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618 response filed Sep. 8, 2020.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618, application filed Apr. 1, 2019, 100 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618, Non-final Office Action dated Mar. 9, 2020.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 16/371,618, Preliminary Amendment filed Nov. 14, 2019.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/178,580, filed Feb. 18, 2021.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, filed Nov. 11, 2022.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220 nonfinal Office Action dated Jul. 17, 2023, 16 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220 Nonfinal Office Action dated Mar. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220 response to nonfinal Office Action filed Sep. 15, 2023, 10 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220 Terminal Disclaimer and Approval, Sep. 15, 2023, 3 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Declaration of John J. Koleng, Jr., Ph.D. Under 37 C.F.R. § 1.132 filed on Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Declaration of Toshiro Sakai, Ph.D. Under 37 C.F.R. § 1.132 filed on Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Exhibits 1-10 to Koleng Declaration filed Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Exhibits 11-20 to Koleng Declaration filed Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Exhibits 21-33 to Koleng Declaration filed Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Exhibits 1-5 to Sakai Declaration filed Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Exhibits 6-8 to Sakai Declaration filed Jun. 13, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Interview Request, Apr. 28, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Interview Summary, May 23, 2023.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 17/985,220, Response to Non-Final Office Action, Jun. 13, 2023, 27 pages.
[cited by applicant]
Lorenz et al., U.S. Appl. No. 61/699,351, filed Sep. 11, 2012.
[cited by applicant]
Lorenz et al., TW102132800, Allowance with English Translation, Jun. 11, 2019, 3 pages.
[cited by applicant]
Lorenz et al., TW102132800, Amended Claims with English Translation, Aug. 29, 2018, 4 pages.
[cited by applicant]
Lorenz et al., TW102132800, Amended Claims with English Translation, Jun. 23, 2017, 6 pages.
[cited by applicant]
Lorenz et al., TW102132800, Amended Claims with English Translation, Sep. 8, 2016, 6 pages.
[cited by applicant]
Lorenz et al., TW102132800, Application for Amendment and Response, Jun. 23, 2017, 7 pages.
[cited by applicant]
Lorenz et al., TW102132800, Application for Amendment, Re-Examination, and Response, Aug. 29, 2018, 10 pages.
[cited by applicant]
Lorenz et al., TW102132800, Decision of Rejection with English Translation, Dec. 28, 2017, 7 pages.
[cited by applicant]
Lorenz et al., TW102132800, Office Action with English Translation, Dec. 22, 2016, 16 pages.
[cited by applicant]
Lu & Park, “Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs,” Int. J. Pharmaceutics 453, 198-214, available online Aug. 25, 2012.
[cited by applicant]
Lu & Rohani, “Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs),” Current Medicinal Chemistry 16, 884-905, 2009.
[cited by applicant]
Mahlin & Bergstrom, “Early drug development predictions of glass-forming ability and physical stability of drugs,” Eur. J. Pharm. Sci. 49, 323-32, 2013.
[cited by applicant]
Mahmoudi et al., “In Vitro Characterization of a Novel Polymeric System for Preparation of Amorphous Solid Drug Dispersions,” The AAPS Journal 16, 685-97, 2014.
[cited by applicant]
Maiwald Patentanwalts, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Manitpisitkul et al., “Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39438335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies,” Clin. Phar…
[cited by applicant]
Marsac et al., “A Comparison of the Physical Stability of Amorphous Felodipine and Nifedipine Systems,” Pharmaceutical Research 23, 2306-16, 2006.
[cited by applicant]
Medivation Press Release dated Aug. 31, 2012, 4 pages.
[cited by applicant]
Medivation Press Release, “Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer,” Feb. 26, 2007, 2 pages.
[cited by applicant]
Midha et al., “Solid Dispersion: A Recent Update,” Int. J. Pharmacol. 1, 17 pages, 2017.
[cited by applicant]
Miller et al.; “A Win-Win Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane Permeability”; Feb. 2012; M…
[cited by applicant]
Mohanachandran, “Superdisintegrants: An Overview,” Int. J. Pharm. Sci. Rev. & Res. 6(1), 105-09, 2011.
[cited by applicant]
Morgen et al., “Polymeric nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug,” Pharm. Res. 29, 427-40, 2012.
[cited by applicant]
Möschwitzer et al., “Drug nanocrystals in the commercial pharmaceutical development process,” Int. J. Pharmaceutics 453, 142-56, available online Sep. 21, 2012.
[cited by applicant]
Mu et al., “Lipid-based formulations for oral administration of poorly water-soluble drugs,” Int. J. Pharmaceutics 453, 215-24, available online Apr. 8, 2013.
[cited by applicant]
Newman et al., “Assessing the Performance of Amorphous Solid Dispersions,” J. Pharmaceut. Sci. 101, 1355-77, 2012.
[cited by applicant]
Newman, ed.,
[cited by applicant]
Ninomiya et al., “Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer,” Int. J. Urology 26(12), 1161-62, 2019.
[cited by applicant]
Novo et al., “Designing synergistic crystallization inhibitors: Bile salt derivatives of cellulose with enhanced hydrophilicity,” Carbohydrate Polymers 292, 119680, 1-10, 2022.
[cited by applicant]
Othman et al., “A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid-Dispersion Formulations of the TRPV1 Antagonist ABT-102, Relative to the Oral Solution Formulation, in Healthy Human Volunteers,…
[cited by applicant]
Pamu et al., “Formulation and In Vitro Evaluation of Gastroretentive Floating Drug Delivery of Valsartan Using Hot Melt Extrusion Technique,” International Journal of Pharmaceutical Sciences and Research 8, 1813-19, 201…
[cited by applicant]
Panini et al., “Myth or Truth: The Glass Forming Ability Class II Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations,” Pharmaceutics 11, 529, 2019 (17 pages).
[cited by applicant]
Patel et al., “Revealing facts behind spray dried solid dispersion technology used for solubility enhancement,” Saudi Pharmaceutical Journal 23, 352-65, 2015.
[cited by applicant]
Patentee's Response to Invalidation Action Against TW Patent 1673051, including English translation, Aug. 21, 2023, 135 pages.
[cited by applicant]
Patil et al., “Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex,” Pharmazie 63, 282-85, 2008.
[cited by applicant]
Paudel et al., “Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and process considerations,” Int. J. Pharmaceutics 453, 253-84, available online Jul. 20, 2012.
[cited by applicant]
Peddy et al., U.S. Appl. No. 15/611,486, final rejection, May 17, 2018, 13 pages.
[cited by applicant]
Peddy et al., U.S. Appl. No. 15/611,486, non-final Office Action mailed Sep. 18, 2017, 9 pages.
[cited by applicant]
Peddy et al., U.S. Appl. No. 15/611,486, preliminary amendment, Jun. 1, 2017, 4 pages.
[cited by applicant]
Peddy et al., U.S. Appl. No. 15/611,486, response to non-final office action, Jan. 18, 2018, 6 pages.
[cited by applicant]
Peddy et al., U.S. Appl. No. 15/611,486, response to Restriction Requirement filed Aug. 23, 2017, 5 pages.
[cited by applicant]
Perrie & Rades, “Themed issue: Improve dissolution, solubility and bioavailability of poorly soluble drugs,” Journal of Pharmacy and Pharmacology 62, 1517-18, 2010.
[cited by applicant]
Pingali et al., “Mixing order of glidant and lubricant—Influence on powder and tablet properties,” Int. J. Pharm. 409, 269-77, 2011.
[cited by applicant]
Pre-Grant Opposition filed against 2875/DELNP/2015, Jul. 7, 2019, 31 pages.
[cited by applicant]
Public Assessment Report (EPAR) of Xtandi@ dated Apr. 25, 2013, 86 pages.
[cited by applicant]
Puri et al., “Investigation of Atypical Dissolution Behavior of an Encapsulated Amorphous Solid Dispersion,” J. Pharm. Sci. 100, 2460-68, 2011.
[cited by applicant]
Qian et al., “Drug-Polymer Solubility and Miscibility: Stability Consideration and Practical Challenges in Amorphous Solid Dispersion Development,” J. Pharm. Sci. 99, 2941-2947, 2010.
[cited by applicant]
Qui et al., “Developing solid oral dosage forms: pharmaceutical theory and practice,” Academic Press (Elsevier), 1st edition, pp. 46, 48, 53, and 54, 2009.
[cited by applicant]
Raijada et al., “A high throughput platform for understanding the influence of excipients on physical and chemical stability,” Int. J. Pharmaceutics 453, 285-92, available online Aug. 24, 2012.
[cited by applicant]
Ray, “Bioavailability Enhancement—Addressing Solubility Challenges: Using Effective Technology & Problem-Solving for Delivery Solutions,” Drug Development and Delivery, Jul./Aug. 2012.
[cited by applicant]
Ray, “Excipient Update: Addressing Challenges With Low-Solubility Compounds: The Importance of Functional Excipients in the Formulation of Amorphous Dispersions,” available at drug-dev.com/excipient-update-addressing-ch…
[cited by applicant]
Response to First Examination Report, 2875/DELNP/2015, May 20, 2019, 45 pages.
[cited by applicant]
Reymond, “Oval pill coated tablets easier to swallow”, Oct. 31, 2006.
[cited by applicant]
Ritschel & Bauer-Brandl eds.,
[cited by applicant]
Rodriguez-Vida et al., “Enzalutamide for the treatment of metastatic castration-resistant prostate cancer,” Drug Design, Development and Therapy 9, 3325-39, 2015.
[cited by applicant]
Romanova et al., “Amorphous Enzalutamide—Non-isothermal recrystallization kinetics and thermal stability,” Thermochimica Acta 665, 134-41, 2018.
[cited by applicant]
Rowe et al., eds.,
[cited by applicant]
Rumondor & Taylor, “Effect of Polymer Hygroscopicity on the Phase Behavior of Amorphous Solid Dispersions in the Presence of Moisture,” Mol. Pharmaceutics 7, 477-90, 2009.
[cited by applicant]
Rumondor et al., “Effects of Polymer Type and Storage Relative Humidity on the Kinetics of Felodipine Crystallization from Amorphous Solid Dispersions,” Pharmaceutical Research 26, pp. 2599-2606, Dec. 2009.
[cited by applicant]
Rumondor et al., “Understanding the Tendency of Amorphous Solid Dispersions to Undergo Amorphous-Amorphous Phase Separation in the Presence of Absorbed Moisture,” APS PharmSciTech 12, 1209-19, 2011.
[cited by applicant]
Samy, “Class II drugs; a dissolution/bioavailability challenge: Flutamide-loaded spray dried lactose for dissolution control,” Int. J. Drug Dev. & Res. 4, 195-203, 2012.
[cited by applicant]
Sandoz AG, Opposition to EP3725778 filed May 11, 2022.
[cited by applicant]
Savla et al., “Review and analysis of FDA approved drugs using lipid-based formulations,” Drug Development and Industrial Pharmacy 43, 1743-58, 2017.
[cited by applicant]
Savla, “Bringing Poorly Soluble Molecules to Market with Bioavailability Enhancement Technologies,” available at americanpharmaceuticalreview.com/Featured-Articles/188660-Bringing-Poorly-Soluble-Molecules-to-Market-with…
[cited by applicant]
Savla,“Softgel Formulations—Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market,” available at drug-dev.com/softgel-formulations-lipid-based-drug-delivery-system-to-bring-poorly-soluble-drugs-to-mar…
[cited by applicant]
Sawicki et al., “Inventory of Oral Anticancer Agents: Pharmaceutical Formulation Aspects with Focus on the Solid Dispersion Technique,” Cancer Treatment Reviews 50, 247-63, 2016.
[cited by applicant]
Sawicki et al., “Validation of a liquid chromatographic method for the pharmaceutical ; quality control of products containing elacridar,” Journal of Pharmaceutical Analysis 2016; 6(4): 268-275.
[cited by applicant]
Sawicki, “Solid dispersions in oncology: a solution to solubility-limited oral drug absorption,” Thesis, Utrecht University Depository, 2017, 229 pages.
[cited by applicant]
Scher et al., “Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy,” N. Eng. J. Med. 367, 1187-97, Aug. 15, 2012.
[cited by applicant]
Scher et al., Trial Protocol for Scher et al., “Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy,” N. Eng. J. Med. 367, 1187-97, Aug. 15, 2012.
[cited by applicant]
Schittny et al., “Mechanism of increased bioavailability through amorphous solid dispersions: a review,” Drug Delivery 27, 110-27, 2019.
[cited by applicant]
Schittny et al., “Particle Forming Amorphous Solid Dispersions: A Mechanistic Randomized Pharmacokinetic Study in Humans,” Pharmaceutics 13, 401, 2021, 16 pages.
[cited by applicant]
Sethia & Squillante, “Solid Dispersions: Revival with Greater Possibilities and Applications in Oral Drug Delivery,” Critical Review in Therapeutic Drug Carrier Systems 20, 215-47, 2003.
[cited by applicant]
Shah et al., “Approaches for Improving Bioavailability of Poorly Soluble Drugs,” Chapter 2 in
[cited by applicant]
Shah et al., “Improved Human Bioavailability of Vemurafenib, a Practically Insoluble Drug, Using an Amorphous Polymer-Stabilized Solid Dispersion Prepared by a Solvent-Controlled Coprecipitation Process,” Journal of Pha…
[cited by applicant]
Shah et al., “Melt extrusion with poorly soluble drugs,” Int. J. Pharmaceutics 453, 233-52, available online Nov. 20, 2012.
[cited by applicant]
Shreya, Pre-Grant Opposition to IN 2875/DELNP/2015 filed Jul. 5, 2019, 335 pages including exhibits.
[cited by applicant]
Siepmann & Siepmann, “Mathematical modeling of drug dissolution,” Int. J. Pharmaceutics 453, 12-24, available online Apr. 22, 2013.
[cited by applicant]
Sigurdsson et al., “Mucus as a barrier to lipophilic drugs,” Int. J. Pharmaceutics 453, 56-64, available online May 29, 2013.
[cited by applicant]
Sim et al., “Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods,” J. Pharmacy and Pharmacology 69, 1707-15, 2017.
[cited by applicant]
Singh & Van den Mooter, “Spray drying formulation of amorphous solid dispersions,” Advanced Drug Delivery Reviews 100, 27-50, 2016.
[cited by applicant]
Singh et al., “Oral formulation strategies to improve solubility of poorly water-soluble drugs,” Expert Opin. Drug Deliv. 8, 1361-78, 2011.
[cited by applicant]
Sinha et al., “Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size, ” Int. J. Pharmaceutics 453, 126-41, available online Jan. 18, 2013.
[cited by applicant]
Sotthivirat et al., “Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364,” Int. J. Pharmaceutics 452, 73-81, 2013.
[cited by applicant]
Srinarong et al., “Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations” (review article), Expert Opin. Drug Deliv. 8, 1121-40, …
[cited by applicant]
Srinarong, “Improved dissolution behavior of lipophilic drugs by solid dispersions,” University of Groningen research database, published 2011, 153 pages.
[cited by applicant]
STADA Arzneimittel AG, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Stewart et al., “Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in Vitro and Oral Bioavailability in rats,” Molecular Pharmaceutics 14, 2437-49, 2017.
[cited by applicant]
Stewart et al., “Practical Approach to Modeling the Impact of Amorphous Drug Nanoparticles on the Oral Absorption of Poorly Soluble Drugs,” Mol. Pharmaceutics 17, 180-89, 2020.
[cited by applicant]
Summary of Product Characteristics (SmPC) of Xtandi® associated with marketing authorization dated Jun. 21, 2013, 85 pages.
[cited by applicant]
Summary of Studies (D49) submitted with Proprietors' Response to Opppositions to EP3725778, Dec. 12, 2022, 10 pages.
[cited by applicant]
Sun et al., “Stability of Amorphous Pharmaceutical Solids: Crystal Growth Mechanisms and Effect of Polymer Additives,” The AAPS Journal 14, 380-88, 2012.
[cited by applicant]
Swarbrick, ed.,
[cited by applicant]
Synthon BV, Opposition to EP3725778 filed May 18, 2022.
[cited by applicant]
Synthon BV, Writ of Summons, Revocation of EP 3725778B1 in Italy filed Jul. 6, 2023, with English machine translation, 103 pages.
[cited by applicant]
Synthon BV, Writ of Summons, Revocation of EP 3725778B1 in The Netherlands filed Jun. 13, 2023, Dutch and Japanese and English translations, 160 pages.
[cited by applicant]
Talukder et al., “Dissolution and Solid-State Characterization of Poorly Water-Soluble Drugs in the Presence of a Hydrophilic Carrier,” AAPS PharmSciTech 12, 1227-33, 2011.
[cited by applicant]
Tanno et al., “Evaluation of Hypromellose Acetate Succinate (HPMCAS) as a Carrier in Solid Dispersions,” Drug Development and Industrial Pharmacy 30, 9-17, 2004.
[cited by applicant]
Taylor, “Physical Stability and Crystallization Inhibition,” Chapter 5 of
[cited by applicant]
Taylor, “Probing the Precipitation Behavior of Poorly Water Soluble Compounds, ” Purdue University, retrieved at zerista.s3.amazonaws.com/item_files/edaf/attachments/413306/original/75_01.pdf, no date provided.
[cited by applicant]
Teja et al., “Drug-excipient behavior in polymeric amorphous solid dispersions,” J. Excipients and Food Chem. 4, 70-94, 2013.
[cited by applicant]
Teva Pharmaceutical Industries Ltd., Opposition to Patent 237604 in Israel, Amended Statement dated Jun. 22, 2023, Hebrew with English translation.
[cited by applicant]
Teva Pharmaceutical Industries Ltd., Opposition to Patent 237604 in Israel, May 18, 2022.
[cited by applicant]
Thakuria et al., “Pharmaceutical cocrystals and poorly soluble drugs,” Int. J. Pharmaceutics 453, 101-25, available online Dec. 1, 2012.
[cited by applicant]
Third Party Observations filed in EP 13766437.1, Jun. 17, 2019, 11 pages.
[cited by applicant]
Third Party Observations filed in EP 13766437.1, Jun. 17, 2019, 5 pages.
[cited by applicant]
Third Party Observations filed in Lorenz EP20177837.0, dated Nov. 2, 2020, 11 pages.
[cited by applicant]
Third Party Observations filed in Lorenz EP20177837.0, dated Nov. 4, 2020, 2 pages.
[cited by applicant]
Third Party Observations filed in Lorenz, EP20177837.0, Apr. 15, 2021.
[cited by applicant]
Third Party Observations filed in Lorenz, EP20177837.0, Mar. 25, 2021.
[cited by applicant]
Ting et al., “Deconstructing HPMCAS: Excipient Design to Tailor Polymer-Drug Interactions for Oral Drug Delivery,” ACS Biomater. Sci. Eng. 1, 978-90, 2015.
[cited by applicant]
University of Colorado Denver, “Enzalutamide adds five months survival in late-stage prostate cancer,” available at www.sciencedaily.com/releases/2012/08/12816101035.htm, 3 pages, Aug. 16, 2012.
[cited by applicant]
Van den Mooter, “The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate,” Drug Discovery Today: Technologies 9, e79-e85, 2012.
[cited by applicant]
Van Eerdenbrugh & Taylor, “Small Scale Screening to Determine the Ability of Different Polymers to Inhibit Drug Crystallization Upon Rapid Solvent Evaporation,” Molecular Pharmaceutics 7(4), 1328-37, 2010.
[cited by applicant]
Van Eerdenbrugh et al., “Crystallization Tendency of Active Pharmaceutical Ingredients Following Rapid Solvent Evaporation—Classification and Comparison with Crystallization Tendency from Undercooled Melts,” J. Pharm. S…
[cited by applicant]
Variankaval et al., “From Form to Function: Crystallization of Active Pharmaceutical Ingredients,” AlChE Journal 54, 1682-88, 2008.
[cited by applicant]
Vasconcelos et al., “Amorphous solid dispersions: Rational selection of a manufacturing process,” Advanced Drug Delivery Reviews 100, 85-101, 2016.
[cited by applicant]
Vasconcelos et al., “Solid dispersions as a strategy to improve oral bioavailability of poor water soluble drugs,” Drug Discovery Today 12, 1068-75, 2007.
[cited by applicant]
Verma & Rudraraju, “Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution rate for Amorphous Solid Dispersion of a Poorly Soluble Drug,” AAPS PharmSciTech 16, 1079-90, 2015.
[cited by applicant]
Vialpando et al., “Evaluation of Three Amorphous Drug Delivery Technologies to Improve the Oral Absorption of Flubendazole,” J. Pharmaceutical Sciences 105, 2782-93, 2016.
[cited by applicant]
Warren et al., “Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility,” Journal of Drug Targeting 18, 704-31, 2010.
[cited by applicant]
Wen et al., “Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges,” The AAPS Journal 17, 1327-40, 2015.
[cited by applicant]
Wenglowsky et al., “Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors,” ACS Med. Chem. Lett. 2, 342-47, 2011.
[cited by applicant]
Williams et al., “Formulating Poorly Water Soluble Drugs,” American Association of Pharmaceutical Scientsts/Springer, Advances in Pharmaceutical Sciences Series 3, 2012, preface, contents, contributors, and chapters 2 a…
[cited by applicant]
Wilson et al., “Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance,” Nature Research Scientific Reports 10, 18535, …
[cited by applicant]
Wilson et al., “Bioavailability Comparison of Various Amorphous Solid Dispersion Formulations of Enzalutamide,” poster, 1 page, 2016 AAPS meeting.
[cited by applicant]
Wilson et al., “Interaction of Polymers with Enzalutamide Nanodroplets—Impact on Droplet Properties and Induction Times,” Mol. Pharmaceutics 18, 836-49, 2021.
[cited by applicant]
Wilson et al., “Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport,” Journal of Controlled Release 292…
[cited by applicant]
Woo et al., “Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers,” Eur. J. Pharm. Sci. 33, 159-65, 2008.
[cited by applicant]
Xtandi® Drug Approval Package webpage printout for Xtandi® capsules (date created Sep. 12, 2012).
[cited by applicant]
Xtandi® Drug Approval Package webpage printout for Xtandi® tablets, Jan. 25, 2021.
[cited by applicant]
XTANDI® European Medicines Agency package leaflet for tablets, last revised Oct. 2018, 6 pages.
[cited by applicant]
XTANDI® European Medicines Agency Summary of Product Characteristics of tablets, updated Jul. 2019, 20 pages.
[cited by applicant]
XTANDI® prescribing information (Europe), Aug. 2012, 3 pages.
[cited by applicant]
XTANDI® prescribing information (JP), Feb. 2018 with English translation.
[cited by applicant]
XTANDI® prescribing information (US), Aug. 2012, 16 pages.
[cited by applicant]